Pathologic response and nodal status guide adjuvant immunotherapy in non–small cell lung cancer after neoadjuvant chemoimmunotherapy: An eastern Asian cohort study
Top Cited Papers
- 27 February 2026
- journal article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82503714)
- Science and Technology Department of Zhejiang Province (2025KY731)
- Chinese Academy of Sciences (2025ZZBS14)
- Natural Science Foundation of Zhejiang Province (LQN26H160021)
- Natural Science Foundation of Zhejiang Province (LHDMY25H100001)
- National Key Research and Development Program of China (2022YFA1304500)
- China Postdoctoral Science Foundation (2024M763330)
This publication has 27 references indexed in Scilit:
- Lung cancer in non-smoking women (LCINSW): from risk factors to precision therapyCancer and Metastasis Reviews, 2025
- Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024Cancer, 2025
- Validation and refinement of the ninth edition ypN descriptor in patients with non−small cell lung cancer receiving neoadjuvant therapyThe Journal of Thoracic and Cardiovascular Surgery, 2025
- Prognostic Implications of Lymph Node Status in Non–Small-Cell Lung Cancer Patients Before and After Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective StudyClinical Lung Cancer, 2025
- Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-AnalysisJournal of Thoracic Oncology, 2024
- Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLCJAMA Network Open, 2024
- Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816ESMO Open, 2023
- Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trialAnnals of Oncology, 2023
- Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant ChemotherapyJAMA Oncology, 2021
- IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant TherapyJournal of Thoracic Oncology, 2020